Company Filing History:
Years Active: 2006
Title: The Innovations of Peter Syribeys
Introduction
Peter Syribeys is an accomplished inventor based in Decatur, GA (US). He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on innovative solutions for treating and preventing infections caused by staphylococcal bacteria.
Latest Patents
Peter Syribeys holds a patent for "Monoclonal antibodies to the fibronectin binding protein and method of use in treating or preventing infections." This patent describes monoclonal antibodies that can bind to the fibronectin binding protein B (Fnbp) of staphylococcal bacteria. These antibodies are generated from a peptide from the D2 region of Fnbp and are advantageous due to their high affinity binding. This property allows them to prevent the adherence of staph bacteria to host cells by impairing the ability of Fnbp to bind to fibronectin. The patent also includes kits and methods for utilizing these monoclonal antibodies effectively.
Career Highlights
Peter Syribeys is associated with Inhibitex, Inc., where he continues to advance his research and development efforts. His innovative work has led to the creation of valuable therapeutic options in the fight against bacterial infections. With a total of 1 patent, he has established himself as a notable figure in the biotechnology sector.
Collaborations
Peter has collaborated with esteemed colleagues such as Joseph M Patti and Pratisksha Patel. These partnerships have contributed to the success of his research and the development of his patented technologies.
Conclusion
Peter Syribeys exemplifies the spirit of innovation in biotechnology through his work on monoclonal antibodies. His contributions are paving the way for new treatments that can significantly impact public health.